Interim PET Analysis in First-Line Therapy of Multiple Myeloma: Prognostic Value of ΔSUVmax in the FDG-Avid Patients of the IMAJEM Study.

21 janvier 2020  | Publications

Bailly C, Carlier T, Jamet B, Eugene T, Touzeau C, Attal M, Hulin C, Facon T, Leleu X, Perrot A, Garderet L, Macro M, Caillot D, Moreau P, Kraeber-Bodéré F, Bodet-Milin C.

https://www.ncbi.nlm.nih.gov/pubmed/30068709